Recommended design features of future clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
about
10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of AmericaCombating antimicrobial resistance: policy recommendations to save livesEvaluation of the Xpert Carba-R (Cepheid) Assay Using Contrived Bronchial Specimens from Patients with Suspicion of Ventilator-Associated Pneumonia for the Detection of Prevalent CarbapenemasesInfluence of bronchoscopy on the diagnosis of and outcomes from ventilator-associated pneumoniaTreatment of severe hospital-acquired and ventilator-associated pneumonia: a systematic review of inclusion and judgment criteria used in randomized controlled trials.Design of clinical trials of antibacterial agents for community-acquired bacterial pneumoniaBiological markers and diagnosis of ventilator-associated pneumoniaQuantitative cultures of bronchoscopically obtained specimens should be performed for optimal management of ventilator-associated pneumonia.Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocolWhite paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogensTelavancin: the long and winding road from discovery to food and drug administration approvals and future directions.Improving Conduct and Feasibility of Clinical Trials to Evaluate Antibacterial Drugs to Treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia: Recommendations of the Clinical Trials Transformation Initiative AntibTreatment for patients with multidrug resistant Acinetobacter baumannii pulmonary infection.The SAATELLITE and EVADE Clinical Studies Within the COMBACTE Consortium: A Public-Private Collaborative Effort in Designing and Performing Clinical Trials for Novel Antibacterial Drugs to Prevent Nosocomial Pneumonia.In-hospital vs. 30-day mortality in the critically ill - a 2-year Swedish intensive care cohort analysis.Characterization of the biological anti-staphylococcal functionality of hUK-66 IgG1, a humanized monoclonal antibody as substantial component for an immunotherapeutic approach.Cost Drivers of a Hospital Acquired Bacterial Pneumonia and Ventilator Associated Bacterial Pneumonia (HABP/VABP) Phase Three Clinical Trial.The deadly impact of extreme drug resistance in Acinetobacter baumannii.Bayesian approach to the design and analysis of non-inferiority trials for anti-infective products.Characterisation of anti-alpha toxin antibody levels and colonisation status after administration of an investigational human monoclonal antibody, MEDI4893, against Staphylococcus aureus alpha toxin.
P2860
Q24601746-0D7DE66D-1B0E-4E7C-B550-C2352B8D3106Q24632857-E37ABB26-B49E-457A-BF86-8F44C75848B5Q28354047-6D65DF0D-D632-437A-B75E-F04967EBFF6DQ30361610-0129CC76-871B-42BF-A0E8-A33F534BEE31Q33846565-F7A47A65-51BD-4BCD-964B-9070A2E5F8EDQ35215307-A975AB5B-D4F3-43E2-8F8C-718553DBC290Q35559332-BA81EB37-08D5-46D8-9F15-CFAFD9B7AC4DQ36667634-F26D2D12-4A36-4789-9139-A1F25804A72DQ36818945-B27C1AF9-0F27-4D43-B9FC-07E32306A457Q36854025-D228C0FE-0CF2-4F93-9724-7BB936882C3EQ38575714-E1A6B173-D393-4712-BB1B-0EE8F414EE52Q38915822-CF35CB01-D405-4893-ACE2-726F496F0E10Q39651458-E9AF64B6-6032-4D5C-9865-71BBCB2AD7DEQ40591899-70241BDF-CA80-4067-9C90-FAE7F2C9E959Q40871870-8C18A603-7FD2-41B6-A658-6BDE83A02FDEQ41832363-39AAD733-4A50-466E-B425-D20CFD5C4A85Q41987099-AA2589A3-CE75-4D69-B079-FB3C1398EF72Q42575612-04515487-CA93-4783-97AF-E7580C64E6C0Q43990228-49A2F67C-6BFF-4A90-93DB-7040DC699094Q50356712-6D29BE4A-F460-4B9D-83A1-84A923AF182B
P2860
Recommended design features of future clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Recommended design features of ...... ssociated bacterial pneumonia.
@ast
Recommended design features of ...... ssociated bacterial pneumonia.
@en
Recommended design features of ...... ssociated bacterial pneumonia.
@nl
type
label
Recommended design features of ...... ssociated bacterial pneumonia.
@ast
Recommended design features of ...... ssociated bacterial pneumonia.
@en
Recommended design features of ...... ssociated bacterial pneumonia.
@nl
prefLabel
Recommended design features of ...... ssociated bacterial pneumonia.
@ast
Recommended design features of ...... ssociated bacterial pneumonia.
@en
Recommended design features of ...... ssociated bacterial pneumonia.
@nl
P2093
P2860
P356
P1476
Recommended design features of ...... ssociated bacterial pneumonia.
@en
P2093
American College of Chest Physicians (ACCP)
American Thoracic Society (ATS)
Brad Spellberg
George Talbot
Infectious Diseases Society of America (IDSA)
Society of Critical Care Medicine (SCCM)
P2860
P304
P356
10.1086/653065
P407
P478
51 Suppl 1
P577
2010-08-01T00:00:00Z